The Impact of Cetuximab Plus AKT- or mTOR- Inhibitor in a Patient-Derived Colon Cancer Cell Model with Wild-Type RAS and PIK3CA Mutation
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Cancer"
DOI: 10.7150/jca.19458
Abstract: Background: Anti-EGFR therapies have been recommended for advanced colorectal cancer (CRC) with wild-type RAS and PIK3CA mutation. However, PIK3CA mutations are a poor prognostic marker and a negative predictor of response to anti-EGFR therapies in… read more here.
Keywords: type ras; ras pik3ca; pik3ca mutation; cetuximab plus ... See more keywords